490P - Clinical evaluation of dendritic cell based vaccines pulsed with WT1 and/or MUC1 for patients with advanced or recurrent cancers

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Immunotherapy
Presenter Shunichi Tsujitani
Authors S. Tsujitani1, M. Tanii2, Y. Yonemitsu3
  • 1Department Of Cell Therapy, National Center for Global Health and Medicine, 162-8655 - Tokyo/JP
  • 2Department Of Medical Oncology, Fukuoka Imax Clinic, Fukuoka/JP
  • 3R&d Laboratory For Innovative Biotherapeutics, Kyushu University, Fukuoka/JP



Dendritic cell (DC)-based vaccines have been expected as one of new therapeutic approaches to treat cancer patients; however, their clinical outcome is not fully elucidated. We here report a single center retrospective study analyzing the survival of patients with various cancers.

Patients and methods

DC-based vaccines pulsed with WT1 and/or MUC1 peptides has been carried out in 180 patients with advanced or recurrent cancers between September 2009 and September 2011. Previous standard chemotherapy failed in most patients and another chemotherapy was given with DC-based therapy. Intradermal injection of 1 x 107 mature DCs was repeated biweekly. After 1 course of treatment (7 times of injection), clinical efficacy was evaluated with RECIST criteria or tumor markers.


In 180 patients, 119 patients completed 1 course treatment. Patient with 0-1 levels of performance status occupied 93% of 119 patients. One-year survival rate of the 119 patients was 57.6% and did not reach to MST. One-year survival rates were 54% in lung cancer (n = 14), 35% in pancreas cancer (n = 14), 100% in colon cancer (n = 9), 50% in ovarian cancer (n = 9), 83% in breast cancer (n = 7) and 86% in gastric cancer (n = 5). In 20 patients with more than 1-year follow-up period and definite assessment of clinical response, 4 (20%) CR, 4 (20%) PR, 9 (45%) SD and 3 (15%) PD were obtained. One-year survival rates were 100% in CR cases, 100% in PR, 67% in SD and 33% in PD.


In patients with 1 course DC-based therapy, survival more than 1 year may be expected, particularly in those with definitive disease control after treatment. DC-based therapy may be suitable to patients with better performance status.


All authors have declared no conflicts of interest.